Bromide Therapy in Refractory Canine Idiopathic Epilepsy

On a retrospective basis, the response to adding chronic oral bromide (BR) to phenobarbital (PB) administration in 23 refractory canine idiopathic epileptics between 1986 and 1991 was studied. The mean age for an observed first seizure was 24 months (range 7 to 72) for all dogs. Thirteen (57%) dogs were males with no breed predisposition observed. All dogs were diagnosed as having idiopathic epilepsy based on normal metabolic and neurologic diagnostic evaluations. Dogs were evaluated before BR therapy for a mean time of 22 months (range 5 to 75 months). Seventeen dogs (74%) received multiple antiepileptic drugs (AEDs) before BR therapy. All animals were maintained on PB at least 4 months before the onset of BR therapy, with a mean trough serum concentration of 37.8 mcg/mL and no improvement in seizure severity or recurrence. Twelve dogs presented with generalized isolated seizures and 11 with generalized cluster seizures (two or more seizures within 24 hours) as their first seizure. The effects of BR therapy were evaluated for a mean time of 15 months (range 4 to 33), with 17 dogs (74%) followed for 12 or more months. The mean BR serum concentration for the 0 to 4 months time period was 117 mg/dL compared with 161 mg/dL for the greater than 4 months period. Overall, response to BR therapy was associated with a reduction in the total number of seizures in 83% of the dogs when compared with their respective pre-BR period. For those followed for 1 year after BR, there was a 53% reduction in the number of seizures compared with the previous 12 months. Furthermore, owners reported a decrease in seizure intensity (65% of dogs) and change to a less severe seizure type (22% of dogs) in those dogs that continued to have seizures. Seizure-free status was obtained in 26% of the dogs with protection continuing up to 31 months in one dog. No correlations could be determined between response to BR and either age of onset of the first seizure or interval from the first AED therapy to BR therapy. Adverse effects of concomitant BR and PB therapy were polydipsia (56% of dogs), polyphagia (30% of dogs), excessive sedation (30% of dogs), and generalized ataxia (17% of dogs). As a result of BR treatment, the PB dosage was reduced in eight dogs (35%). In conclusion, concomitant BR and PB was well tolerated in dogs of this study and was effective in treating refractory canine idiopathic epilepsy, regardless of prior interval of seizure activity or previous treatment. (Journal of Veterinary Internal Medicine 1993; 7:318–327. Copyright © 1993 by the American College of Veterinary Internal Medicine.)     

犬肿瘤脾脏摘除治愈血小板减少性紫癜病例

10岁杂交老犬,周身出现紫癜,脾脏检查有肿瘤生成,经2次保守治疗紫癜褪去,都是间隔不到1周又复发,后通过摘除犬脾而得到治愈.     

Canine Idiopathic Dilated Cardiomyopathy. Part II: Pathophysiology and therapy

Dilated cardiomyopathy (DCM) in dogs is characterized by ventricular and atrial enlargement, and systolic and diastolic dysfunction, with congestive heart failure (CHF) often developing at some stage. With greater understanding of the impact of neuroendocrine stimulation in heart disease, the understanding of the pathophysiology for CHF has changed considerably. It is no longer considered only to be a simple haemodynamic consequence of pump dysfunction, but is now characterized as a complex clinical syndrome with release of many neurohormones, which are believed to have impact on the progression of disease. This change in our understanding of the pathophysiology of CHF has important therapeutic implications. There are strong indications, although not yet proven, that drugs designed to influence the neuroendocrine activity, such as Angiotensin Converting Enzyme (ACE) inhibitors and beta-receptors antagonists, are efficacious as adjunct therapy of heart failure attributable to DCM in dogs. The benefits of drugs designed to influence the myocardial contractile state (positive inotropes) have not been fully evaluated. However, evidence has emerged in recent years indicating that new types of positive inotropes may be beneficial in dogs with DCM. This review focuses on the neuroendocrine aspects of DCM and their possible therapeutic implications and the place for long-term inotropic support in dogs with DCM.     

Canine hyperlipidaemia

Hyperlipidaemia refers to an increased concentration of lipids in the blood. Hyperlipidaemia is common in dogs and has recently emerged as an important clinical condition that requires a systematic diagnostic approach and appropriate treatment. Hyperlipidaemia can be either primary or secondary to other diseases. Secondary hyperlipidaemia is the most common form in dogs, and it can be a result of endocrine disorders, pancreatitis, cholestasis, protein‐losing nephropathy, obesity, as well as other conditions and the use of certain drugs. Primary hyperlipidaemia is less common in the general canine population but it can be very common within certain breeds. Hypertriglyceridaemia of Miniature Schnauzers is the most common form of primary hyperlipidaemia in dogs but other breeds are also affected. Possible complications of hyperlipidaemia in dogs include pancreatitis, liver disease, atherosclerosis, ocular disease and seizures. Management of primary hyperlipidaemia in dogs is achieved by administration of ultra low‐fat diets with or without the administration of lipid lowering drugs such as omega‐3 fatty acids, fibrates, niacin and statins.     

Canine bacteruria

Urine from 237 dogs submitted for euthanasia was collected directly by needle aspiration from the urinary bladder. The bacteriological findings were correlated with the sex and age of the dogs. E. coli was the most frequent species found. The overall incidence of bladder infection was 6–2% for males and 26–6% for females. Bladder infection can be categorized on the basis of occurrence in either very young or in older dogs. The infection incidence increased linearly in bitches older than 4 years, ending at a 50% frequency in those more than 10 years old. Pyometra frequency also increased after 4 years of age and this pattern may indicate a common causative factor for urinary tract infection and pyometra. This investigation shows that subclinical urinary tract infection is common in dogs and is related to age in bitches.     

Canine pyoderma

Bacterial skin disease (or pyoderma) is a common canine disorder. It is usually associated with coagulase-positive staphylococci which multiply on skin and induce disease as a result of a number of poorly understood mechanisms. Pyoderma usually occurs as a result of another underlying disorder. Primary causes include hypersensitivity, ectoparasites and metabolic and immunological disorders. A detailed and systematic investigation is mandatory so that the underlying cause is discovered if possible. A number of cases are idiopathic. Pyodermas may be classified according to depth of infection as this affects the type and duration of therapy required and the prognosis. Deeper forms require more aggressive and prolonged therapy. Management of pyodermas depends on the identification and correction of the underlying cause along with adjunct therapy using systemic and topical antimicrobial agents. Idiopathic cases may require protracted or even lifelong therapy with such medicaments. Glucocorticoids are generally contraindicated in the management of pyoderma.     

犬的繁殖

犬是单次发情的,小型品种犬到达性成熟要比大型品种早些,公犬的性成熟比母犬延迟几周,野犬只在冬季交配,而家犬四季都能繁殖,但发情的频率趋向于春末和冬初。